Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . • Sisram Medical Ltd 復 銳 醫療 科技 有限公司 * ( Incorporated in Israel with limited liability ) ( Stock Code : 1696 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30 , 2026 FINANCIAL HIGHLIGHTS For the six months ended June 30 , 2026 : Revenue was US $ 171.4 million , representing an increase of 3.6 % compared with the same period of 2025 . Revenue from International markets ( excluding North America ) was US $ 127.0 million , representing an increase of 16.7 % compared with the same period of 2025 . Revenue from Injectables was US $ 22.2 million , representing an increase of 54.2 % compared with the same period of 2025 . Revenue from Medical Aesthetics ( excluding North America ) was US $ 97.1 million , representing an increase of 7.2 % YoY . Gross profit margin was 56.7 % , compared with 60.0 % in the same period of 2025 . Adjusted net profit was US $ 5.0 million , compared with US $ 12.0 million in the same period of 2025 . INTERIM DIVIDEND The Board resolved not to declare any interim dividend for the six months ended June 30 , 2026 . RESULTS HIGHLIGHTS The board of directors ( the “ Board ” ) of Sisram Medical Ltd ( the “ Company ” or “ Sisram ” ) is pleased to announce the unaudited consolidated results of the Company and its subsidiaries ( collectively referred to as the " Group ” or “ we ” ) for the six months ended June 30 , 2026 ( the " Reporting Period ” ) , together with the comparative figures for the corresponding period in 2025. The results have been prepared in accordance with International Financial Reporting Standards ( the " IFRSS ” ) . · 1 –